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Abstract  
The down-stream processes where new product prospects undergo pilot testing and 
adjustments before market launch can have significant impact on development speed. 
Previous literature has primarily pointed to firm traits as influential factors to speed. 
However, product specific measures such as technical innovativeness may be a critical factor 
when going through the crucial late stages of development. We have limited knowledge of the 
relation between product newness and the speed of NPD, and how this may be related to firm 
size and partnering strategies during development. Combining product traits with firm 
resources relevant to late stage development speed can enrich our understanding of time-to-
market in the aim of improving this crucial measure of NPD. 
The research model is tested on a dataset of all new drug developments approved for the US 
market 2000-2010. The results show that newness of a product, small size of a development 
company and partnering for external resources all increases the speed of late stage 
development speed.  
The results show that technical innovativeness of products in late stage development has the 
consequence of extending this important process of NPD. Also, partnering strategies as well 
as small development companies have a negative effect on the speed of late stage 
development. These results have the implications to managers, that in the case of developing 
technical innovative products, the allocation of resources in the development process should 
be considered accordingly.  
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Introduction 
Speed of new product development is a crucial factor in product performance as this may 
diminish costs and contribute to competitive advantages (Gold, 1987; Mahmoud-Jouini, 
Midler, & Garel, 2004; Vesey, 1992). Especially in industries where patent life circles are an 
important pre-requisite for product performance the time to develop a new product is 
essential. Previous literature primarily focuses on firm level measures to study influential 
factors for development speed (Acur, Kandemir, De Weerd-Nederhof, & Song, 2010; 
Carbonell & Escudero, 2010; Jr, 1988). However, the technical innovativeness of a new 
product is a key measure in times where increased innovation is a preferred strategy for 
production firms.  
Existing literature are not unanimous in the effect of product innovativeness on product 
success. Some studies point to a positive influence on market performance (Talke & Salomo, 
2009; Zhou & Tse, 2005), where others show no effect between the two (Danneels & 
Kleinschmidt, 2001; Salomo, 2007; Mohan V Tatikonda & Rosenthal, 2000). 
Common for studies on product newness is however the challenges such technical 
innovativeness have for new product development processes (Danneels & Kleinschmidt, 
2001; Kock, Gemünden, Salomo, & Schultz, 2011). Technical innovativeness of new 
products bring by challenges of uncertainty often followed by a need to restructure internal 
resources and extend the available knowledge base (ibid).  
As there are many differentiated results of technical innovativeness on success, but 
undisputed literature pointing to the challenges of innovativeness, it is relevant to connect 
innovativeness on development speed, which is a highly pursued strategy in production firms. 
A broader understanding of the development process of technical new products can increase 
managers knowledge applied for resource allocations strategies.  
Existing literature on development speed is limited in the method of measuring time-to-
market and product newness, as these measures are often subject to internal firm evaluation 
based on survey studies (Chen, Reilly, & Lynn, 2012; Lynn, Abel, Valentine, & Wright, 
1999; Mcnally, Akdeniz, & Calantone, 2011). This paper is aiming to meet this gap by 
studying data from a product development process where external quantitative measures for 
development speed can be applied. In the Pharmaceutical industry new products undergo 
extensive testing before obtaining approval for market launch. After intensive laboratory 
research and animal testing, successful compounds enter the next stage of development, the 
clinical trial phases, where the new products are tested on humans. Here strict rules are being 
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followed, defined by regulatory authorities such as the FDA (US Food and Drug 
Administration) and EMEA (European Medicines Agency), who also give the final approval 
to the new products. New pharmaceutical products are therefore subject to external regulatory 
surveillance and final market approval leaving an external and objective measure of speed. 
The initiation date and termination date of drug testing are thus applied in this study. 
Further, every new drug indication is connected to an original patent, which thereby supply 
quantitative patent data as a proxy for technical innovativeness. This study therefore apply a 
dataset off all new approved drugs on the US market between 2000-2010 measuring the time 
of the critical development phase of clinical trials before market launch connected to the 
original patents of the drugs. 
Along side the aim of decreasing development time of the demanding clinical trials, the 
pharmaceutical industry is highly focused on technical newness. Introducing blockbuster 
drugs to the market mainly covers the large R&D expenditures (blockbusters = a drug with 
annual revenue of at least $1 billion (Gassmann, Reepmeyer, & von Zedtwitz, 2008) and with 
a large number of existing treatments on the market there is a need to develop truly new drug 
candidates in order to be approved. The industry are therefore pursuing two primary 
strategies; 1) decreasing time-to-market of development in order to decrease the high R&D 
budgets, and 2) the discovery and development of technical new products to the market in 
order to reach blockbuster status of new drug candidates.   
Even though this two sided strategy are a key issue in pharmaceutical product development 
the focus on both time-to-market and product innovativeness are issues easily generalized to 
many other industries, which is also prevalent in the vast amount of literature on both areas 
(Chen et al., 2012; Kock et al., 2011). This follows the challenges in the literature on 
development speed, which are not unanimous in determining a relationship between market 
success and developments speed; Some literature support the notion that speed prospers 
market success (R. Calantone, Garcia, & Dro, 2003; González & Palacios, 2002; Lynn et al., 
1999), which follow the challenge of introducing new products on the market fast in order to 
exploit the patent life cycle. However, speed may also come at some costs, and literature 
therefore also suggest that speed may not always be the most desirable strategy – or not the 
most important measure when aiming at market success (Chen et al., 2012; Cooper & 
Kleinschmidt, 1994). This study aims at gaining further understanding of the relationship 
between development speed and technical innovativeness. As much literature on technical 
innovativeness suggests a highly challenging development process it is relevant to study if 
this will be at the expense of speed. This study therefore builds on the notion, that speed may 
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not always be the most prevalent strategy; the innovativeness of the product under 
development may create circumstance, which create difficult circumstances for optimization 
of development speed.  
In order to enrich the research model a proxy for the internal resources available at the firm, 
and the external strategy applied in relation to external technology sourcing are applied. The 
relation between 1) firm size, and 2) partnering level on development speed are thus studied. 
Integrating these measures in the research model can indicate if firm size and partnering as 
proxies for internal and external resources influences development speed when controlled for 
technical innovativeness.  
 
Research model and hypothesis´   
Much research have been conducted on the speed of NPD as a general process, or focused 
around the frond-end of development (Aagaard & Gertsen, 2011; Chen et al., 2012; Veryzer, 
1998). The dependent variable here is development speed; an issue area which have been 
studied under different terminologies; time-to-market (MV Tatikonda & Montoya-Weiss, 
2001), innovation time (Mansfield, 1988), project duration (Ulrich, Sartorius, Pearson, & 
Jakiela, 1993). The focus in this study is on development time, and therefore not on e.g. time 
from initial idea discovery until market introduction. This study focuses on the often-
neglected later stages of development after initial idea generation and prototype development 
is finalized.  
Literature on the development of technical innovative products have pointed to the challenges 
of preparing the organization for the new structures often needed when radical products are 
developed for the market (Danneels & Kleinschmidt, 2001; Kock et al., 2011). Radical 
innovations will often reach beyond existing capabilities in line with current portfolio, and 
thereby induce a need for complementary capabilities in order to extend the firms knowledge 
base (Teece, 1986, 1996). This knowledge base both refers to technical capabilities, but also 
market intelligence to support the new product application on the market. These activities 
relevant for technical innovative products are however relevant to study in relation to the 
important time-to-market measure, which is a key parameter for the NPD performance.   
 
Technical innovativeness 
Previous research has studied the impact of innovativeness on speed in the front-end of 
development (Aagaard & Gertsen, 2011). It is here recognized that radical new innovations 
have a longer front-end development time. Newness of a product is often followed by a high 
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degree of uncertainty, which leads to increased need of new information (Chen et al., 2012; 
Veryzer, 1998). Further, technological newness can bring by organizational challenges, as 
new competences and processes might be needed in order to develop this new product to the 
market (Kock et al., 2011; Teece, 1986).  
This technological uncertainty that follows product newness can thereby result in longer 
development time (Gupta, Raj, & Wilemon, 1985). The challenges of product newness are 
also applicable in the later phases of development where the new products are being tested 
before launch. It is therefore relevant to test if newness also influences the time after 
discovery and therefore the late stage of development.  
The technical newness of a product candidate is in this study measured by patent citations. If 
a product has few or none backward citations in the patent application it is considered new to 
the market. This is in line with the above argument, that development of new products 
experience higher degree of uncertainty. If a patent has fewer backward citations, less 
previous knowledge can be drawn upon during the development of the new product. With a 
high level of references to previous patents it can be expected, that previous research projects 
have acquired information relevant for the new product development process. Technical 
newness defined by few backward citations thereby represents an opportunity to bring by 
something radical to the market. However, in the development of such technical new products 
there will be a need to extend the existing knowledge base and the resources available in 
relation to the existing portfolio. These efforts may extend the products time in development 
and thus have a negative effect on speed.  We therefore hypothesis:  
 
Hypothesis 1: Technical innovativeness has a negative effect on late stage development speed 
 
 
Figure 1: Conceptual framework 
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Company size  
Company size has often been applied as a proxy for firms internal resources (Chandy & 
Tellis, 2000; Song, Im, Bij, & Song, 2011), as large companies will often have more 
extensive financial, human and portfolio assets than smaller firms. The large size of a 
company may result in organizational challenges such as increasing layers of management, 
which may challenge a process of innovation (Chandy & Tellis, 2000). This may especially 
apply in the front end of NPD, where new ideas are created and prototypes developed.  
In the later stages of product development it has previously been recognized that large 
companies have advantages, as they have experience in the complex processes of product 
testing (R. J. Calantone & Benedetto, 2000; Danzon, Nicholson, & Pereira, 2005). Calantone 
and Benedetto (2000) point to market power as an influential factor in time-to-market. Market 
power is here defined as companies with strong brand equity or large companies with cost 
advantages. This study focuses on firm size in the perspective of late stage development.  
Large companies can exploit that they have existing competences within the technologies and 
apply this experience in the resource demanding late stages of development (Danneels & 
Kleinschmidt, 2001; Danzon et al., 2005). We therefore hypothesis:  
 
Hypothesis 2: If the development company of the late stages of development is large, this will 
have a positive effect on the development speed. 
 
Partnering strategy 
Previous studies on alliances in development processes have been pointing to the importance 
of a co-development strategy and formal management structures in order to obtain and sustain 
these positive outcomes of the relation (Mowery, Oxley, & Silverman, 1997; Powell, Koput, 
& Smith-Doerr, 1996). One of the central measures in such an alliance coordination strategy 
is a clear definition of the individual and joined tasks of the alliance partners (Das & Teng, 
1998). This process may be complicated and issues such as decision proceedings, 
performance measures and common goals are also central measures in the success of co-
development (ibid). These general challenges also apply to the approval process, as studies 
from the pharmaceutical industry points to some negative effects of alliances if especially 
small companies enters to many partnerships, as such firms may have a lack of resources to 
monitor and manage these collaborations (Deeds & Hill, 1996).  
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Previous research on development speed has primarily observed the whole process of NPD 
including idea generation, prototype development and testing. In this perspective partnerships 
in NPD may positively affect speed due to the complimentary capabilities mentioned earlier. 
However, as this study is exploring late stage development and the influential factors to 
product testing, partnerships may be representing some challenges to speed. As mentioned 
above partnerships also represent a coordination challenge, which is further enhanced in the 
regulatory heavy testing phases. In-house developed products here have the advantaged of 
easier coordination through the demanding prototype testing phases. We therefore hypothesis: 
 
Hypothesis 3: If more than one company is involved in the testing process the development 
speed is longer 
 
Methodology and data collection 
Previous studies of development speed are primarily based on data where speed measures is 
subject to internal review. Internal stakeholders are here asked their judgment of development 
speed in relation to related measures (R. J. Calantone & Benedetto, 2000; Lynn et al., 1999). 
This method is often applied while a measure of development time is difficult to identify and 
collect. This study has therefore chosen to focus on the Pharmaceutical industry, as the 
process applied here identifies initiation and approval markers for late stage development.  
There are three central phases of clinical research in the testing process of new 
biotechnological or pharmaceutical drugs, i.e., phase I – III. The trials intensify with respect 
to the number of participants throughout the three phases. In phase I there are usually less 
than 100 participants (i.e. individuals involved in testing the new pharmaceutical product) 
where safety is the prime goal. Phase II requires 100 – 300 participants, and here longer-term 
effects and determination of exact dosage is the main aim.  Phase III requires 1000 or more 
participants to be included in the trials, where the new product’s effects are compared to an 
equivalent benchmark product (Hathaway, Manthei, Haas, & Meltzer, 2009, FDA 1 ; 
clinicaltrials.gov2).   
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm090410.htm. Retrieved 
October 12th 2010	  
2 Clinicaltrials.gov is an institutions under the US National Institute of Health supervising and 
documenting clinical trials. http://clinicaltrials.gov/ct2/info/understand. Retrieved October 
12th 2010 
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During the development process of clinical trials the Pharmaceutical industry are in close 
contact with the regulatory authorities such as the FDA as these actors have the final decision 
power concerning new products approval. Before entering into the trial phases an IND – 
investigational New Drug application – is submitted and approved, and after the last of the 
three trial phases is conducted a NDA – New Drug Application is submitted to the authorities 
to obtain final market approval.  
 
 
Figure 2: Process of late stage drug development. IND=Investigational New Drug, 
NDA=New Drug Application 
 
To study the speed of product testing in the Pharmaceutical industry, data is collected for all 
approved drugs on the US market between 2000-2010.  Here the IND time and the NDA time 
is identified and applied to measure the speed of late stage development. The speed of 
development measure is therefore not based on a subjective internal measure among internal 
firm actors. The dataset is a total of 230 subjects (all new approved drugs on the US market 
2000-2010), and are further enriched by matching the drugs with data from R&D reports 
(R&D Focus), and patent data based on the original drug application.  
 
Measures 
Following is an overview of the measures applied in the regression model to test the 
hypothesis proposed in this paper.  
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Table 1: Overview of measures 
Measure Measurement method Applied as 
IND sub. Year of Investigational New Drug (IND) submission 
Applied to the development speed 
estimation  
NDA Sub. Year of New Drug Application (NDA) submission 
Applied to the development speed 
estimation 
Development speed Time (months) from IND submission to NDA submission (numerical variable) Dependent variable 
Product newness Backward citations of original patent (Numerical variable) Explanatory variable 
Firm size  Large = Top 50 of industry by revenue at development year (dichotomous variable) Explanatory variable 
Partnering  
Single company development process or more 
than one partners during development 
(dichotomous variable) 
Explanatory variable 
Review type Fast track (Priority) or not (dichotomous variable) Control  
Therapeutic area Product specification – (Categorical variable -10 categories)  Control 
M&A Merger or Acquisition during development (dichotomous variable) Control 
FDA approval year Year of FDA approval (Categorical variable -10 categories) Control 
 
Development speed: As the prototype testing phases in the Pharmaceutical is highly regulated 
it is possible to obtain the time of entering into testing – the clinical trials – and time of 
finishing clinical trials. Before entering into the clinical trial phases, firms have to submit an 
IND – Investigational New Drug application to the FDA. This applications includes results of 
the early stage discovery and laboratory testing results, and if accepted the drug can move on 
to the clinical trial phases. If the drug manage to succeed through the challenging 3 testing 
phases of clinical trials, the firm can submit an NDA – New Drug Application – and based on 
this obtain approval for the market. The dataset applied in this paper are all the approved 
drugs by the FDA between 2000-2010, and therefore all drugs with both an IND and NDA. 
The speed of development can thereby be calculated as the time from IND submission, to 
NDA submission.  
Technical innovativeness: Technical newness of the product candidate going through the 
product testing process is measured by patent data. Each new product candidate is connected 
to an original patent, which can be identified in R&D reports. These patent numbers is 
subtracted and individual patent reports identified from the original patent database whether 
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filed at the USPTO, EPO or other databases, and therefore subtracted through the WHO 
database. From the patent reports the backward citations count is subtracted as a measure for 
technical newness of the new drug candidate. If a patent has few or no backward citations, 
and therefore is not referring back to previous innovations, it is defined as newer, than 
products with more backward citations, and therefore product candidates based on previous 
technological innovations.  
Partnering: Companies enter into various alliances during development based on the prospect 
of the product candidate. It is therefore often observed that more than one company is active 
during the development phases of a new product, as firms look outside their own capacity to 
gain external resources for the development process. One partner may have discovered the 
new product and developed the prototype, and hereafter entered into a partnership with other 
firms in the aim of entering the product on the market. Other firms apply a strategy where the 
development process is based on internal resources alone and therefore a single firm strategy.  
To measure whether the development is based on primarily internal resources alone, or a 
strategy based on incorporating external resources the partnering model for the individual 
drug development in the dataset is observed. The variable partnering therefore measures if the 
development process is based on a single company strategy or if more companies than one are 
integrated in the development process. R&D reports (R&D focus) for every drug candidate 
are manually studied and single fir strategy vs. multi firm development strategies indicated in 
the dataset. (0=single firm, 1=more than one firm)    
Firm size: Firm size is defined as a measure of annual revenue in order to apply a measure, 
which both includes ongoing development processes and dynamics of the Pharmaceutical 
industry. If a sales measure were to be applied, it would have the risk of a skewed annual 
measure dominated by blockbuster products. Annual revenue also includes the R&D 
investments, which are a key cost in the pharmaceutical industry. To measure the size of the 
development firm it would not give a proficient picture to subtract size from a market report 
as of 2012. As the data set is based on product launch from 2000-2010 on the US market, the 
individual product launch data is applied to evaluate firm size. Annual revenue of the last 10 
years (2000-2010) is therefore applied to evaluate size. These figures are applied from 
pharmaexec 50 – an annual market analysis of the top 50 Pharmaceutical (and Biotech) 
companies by revenue. This measure of firm size will give a more accurate and dynamic 
understanding of size of the involved companies in the individual product development 
processes. As the industry includes a large number of smaller firms the measure of size is 
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coded into a dichotomous variable where the top 50 are grouped in larger firms, and all others 
in smaller firms (0=small, 1= large). 
 
Controls 
Review type: As the demanding model of new product development is recognized in the 
pharmaceutical industry, initiatives has been engaged to speed up the process for some type of 
products. The fast track model was therefore initiated in 1998 to speed up the regulatory 
process for drugs treating life-threatening and serious diseases, by assigning more meeting 
with the FDA and reduced regulatory review time. When studying a dataset of new drugs on 
the US market it is therefore important to control for the type of review a drug is assigned. 
Every product in the dataset is therefore assigned a coding indicating whether the process is 
standard or priority (fast track), which is thereby controlled for in the analysis.   
Therapeutic area: It is well known within pharmaceutical product development, that some 
disease areas have a more complex and therefore an average longer development time than 
others. Central nervous system is an example of a product/disease area, which per definition 
is complex, as central nervous system diseases and hereunder psychological illnesses often 
have a longer treatment period. The processes where new products are tested on humans are 
therefore often long in central nervous system diseases, and should therefore be controlled 
for. All drugs in the dataset is therefore categorized in ten therapeutic areas in line with 
common definitions in the industry and clinical research: Anesthetic, Anti-infectives, Anti-
neoplastics, cardiovascular, Central Nervous system, diagnostic, endocrine, gastrointestinal, 
immunologic, respiratory 
Mergers and Acquisitions: The Pharmaceutical and biotechnological industry are well known 
for its heavy activity of mergers and acquisitions over the years. Due to a substantial and 
continuous increasing cost of drug development mergers and acquisitions is a commonly used 
strategy in the industry. Large companies have the financial strength and experience in the 
extensive late stage clinical trials, whereas smaller development companies are challenged in 
the expensive testing phases, which is a main reason for the extensive M&As in the industry. 
It is therefore controlled for in this study, if a development company have been directly 
involved in a M&A during the development process. This information is found in the 
individual drugs development report in R&D Focus. 
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FDA approval year: The regulatory demands are continuously changing in the 
Pharmaceutical industry resulting in increasing protocol design complexity (DiMasi, Hansen, 
& Grabowski, 2003; Getz, Campo, & Kaitin, 2011). Further, the increasing cost and time 
spend on clinical trials have resulted in a change of the testing process model integrating more 
partners via outsourcing strategies and thereby increasing layers of management 
(Bodenheimer, 2000; Mehta & Peters, 2000). Including the year of approval as a control 
variable thereby controls for these vast changes in the business model of clinical trials over 
the years.  
 
Table 2. Correlations of measures 
 Dev. 
time 
TA Review 
type 
M&A FDA Yr Firm 
size 
Partnering TechInn 
Development 
time 
        
Therapeutic area .05        
Review type .07 -.21***       
M&A .01 -.04 -.02      
FDA approval 
year 
.03 .17*’ -.08 -.01     
Firm size -.18*** -.04 -.09 .26*** -.06    
Partnering .11* .09 -.19*** .18*** .03 -.04   
Tech. Inn. -.13* -12* .09 -.04 .03 .03 -.06  
*=p < 0.1,  **=p < 0.05, ***=p < 0.01  
 
 
 
Results and discussion 
Technical newness pressures the time-to-market 
The results of the regression analysis reveal that product newness has a negative effect on late 
stage development speed (table 3). We can thereby confirm hypothesis two as new products 
defined by patents citation patterns result in increasing development time.  
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Table 3: Regression model 
*=p < 0.1,  **=p < 0.05, ***=p < 0.01  
 
The result illustrates a great challenge when developing really new products, with the 
possibility to be a first mover in the market. Besides the risk of failing product requirements, 
the development process is longer than products based on previous developments.  
Interesting in this dataset is, that all of the drugs in the dataset are original new drugs, and 
therefore new to the market. All the products in the dataset are therefore new to the market, 
but the patent data analysis scale out how new these products are, and test this on the 
development speed. This study can thereby supply the industry with insights into the 
challenges of going through the long development process with a product not referring back 
to previous knowledge. Future studies should take these results and test, if this will also affect 
the final market success after launch.   
 
More internal resources support speed of development 
The results of the regression analysis show, that drugs developed in the alter phases by a large 
Pharmaceutical company have shorter development times. Drug development in the 
challenging late phases of development by one of the top 50 Pharma companies is faster 
through the prototype testing process, than drugs developed by small sized firms. This thereby 
confirms hypothesis 2, which argues, that larger companies have an advantage in later stages 
 Model 1 Model 2 
Predictors B t-value B t-value 
  Control variables      
Therapeutic area .036 .23 -.49 -.31 
Review type 5.47 .65 8.13 .97 
M&A 4.485 .55 3.86 .34 
FDA approval year 1.4 .94 1.30 .91 
  Explanatory variables     
Firm size   -22.58** -2.46 
Partnering     18.40** 2.18 
Technical innovativeness   -.76* -1.66 
     
R2 .008 .085 
Adjusted R2 -.012 -.052 
df  193 190 
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of development, due to the vast amount of resources required (R. J. Calantone & Benedetto, 
2000). Further, the experience large firms often have due to a broader portfolio is also an 
influential factor mentioned in previous literature (Danzon et al., 2005). Ongoing relations 
with key stakeholders is more likely with large companies, as they have more late stage 
clinical trials, and therefore opportunity to develop ongoing and close relationship to 
stakeholders. Another important actor in these stages is the regulatory authorities, which in 
the case of the US market is the US Food and Drug Administration (FDA). Previous literature 
also point to the importance of large companies experience in working with the complex 
regulatory requirements, and relations to the authorities. Previous research therefore indicates 
that large companies have an advantage in the later stage of development, where new 
products go through clinical trials. This study follows this line of argument and supports the 
advantages large companies experience in the demanding testing process.  
 
Don´t partner up for the sake of speed 
The results of the regression analysis show a significant and negative effect of partnering on 
development speed. Therefore if more than one company is involved in a NPD process, the 
testing process is longer, than products development by a single company strategy. 
Companies whom have developed a new drug candidate all the way through the development 
process and through market launch experience a shorter development time. This result builds 
on the literature on partnering models and their influence on NPD processes (Mowery et al., 
1997; Powell et al., 1996; van Beers & Zand, 2014). Partnerships are previously mentioned to 
have advantages in the front-end of NPD, where new products are being discovered and 
prototypes development, as companies with complimentary capabilities can join efforts in the 
complex drug discovery phase. However, in the later stages of development single company 
development have advantages, which influences the important speed to market. Single 
company development prevents the complex process of coordination, which is especially 
prevalent in relation to the highly regulated testing phases. In later stages single company 
efforts can speed up the process, by applying a less complex management structure, which 
often follow with partnerships in development. This is interesting in a time where much 
research point to the need for external resources in new product development. This result 
illustrate, that single company efforts is an advantage when undergoing a complex late stage 
development process, where adding to the complexity may extent the time to market.  
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Fast or new – the development trade off 
Previous literature on partnering strategies point to patents, technology intake and prior 
experience as the main drivers for collaboration (Danneels & Kleinschmidt, 2001; van Beers 
& Zand, 2014). The motivations for partnering together with the technological capability 
intake challenges in cases of technological innovative products indicate that in cases of 
radical product development partnering can be a sound strategy to optimize missing 
capabilities.  
The results of this study showing that both partnering and technological innovativeness is 
slowing down the development process supports previous studies on the challenges in 
developing radical products for the market. The purpose of this study is not to add to the 
literature on market success of radical products (Talke, Salomo, & Mensel, 2006; Zhou & 
Tse, 2005). This study instead supports the understanding that developing truly new products 
to the market follows a path of challenges, which will slow down the development process. 
When designing and allocating resources for development processes of radical innovations 
managers should therefore be aware of the often-extensive costs linked to such endeavors.  
The single firm development process, which can stimulate the time-to-market challenge, may 
not be a preferable strategy when the aim is to support radical innovations where an extension 
of the existing knowledge base is needed. Partnering strategies are here a relevant strategy so 
support the need for complementary capabilities (Danneels & Kleinschmidt, 2001; van Beers 
& Zand, 2014) – especially in the cases where technical new products are being under 
development for market launch.  
In the empirical context of this study – the pharmaceutical industry – the results show that 
large firms whom develop less innovative products in a singular firm strategy are faster at 
getting to the marketplace. It is here notable that all of products in the dataset are new to the 
market in the sense, that they are original products based on a patent life cycle. Follow-on 
drugs, which copy existing technical innovations, are not included in the dataset. All of the 
products in the dataset are therefore new to the market in order to get through the clinical 
trials and prove better than existing treatments. The results of this study however show, that 
within the frame of innovative products the most technical innovative and thereby the 
products referring to the fewest existing technical specifications will take longer to get 
through development than innovations which build on existing technologies. The information 
stored in the initiation idea discovery of the patent application can thereby tell pharmaceutical 
companies something about the resource allocation that they should consider in the later 
phases of product development.  
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Managerial implications  
The results indicate that technical innovativeness of products in late stage development has 
the consequence of extending this important process of NPD. Also, partnering strategies as 
well as small development companies have a negative effect on the speed of late stage 
development. This together indicates that smaller firms who enter partnering strategies and 
apply technical new products in pilot-testing’s are slower at entering the new product to the 
market. These results have the implications to managers, that in the case of developing 
technical innovative products it should be considered, that the speed of development will 
increase. When radical new products are discovered, which have few references to previous 
techniques, the allocation of resources in the development process should be considered 
accordingly.  
 
Limitations  
Testing speed dynamics on a sample on cases in the same industry is challenging to 
generalizations, but also decrease noise from market differences that may influence speed. 
The conclusions can thereby supply information, which is not effected by market diversity 
such as differences in market newness or development processes. This is different from many 
previous studies, which apply a cross industry dataset (Chen et al 2012). It should hover be 
noted that the data applied in this study represents an industry which in many cases may 
represent some unique traits. However, these traits also represent some unique research 
opportunities, as the highly controlled development process bring by an objective speed 
measure based on regulatory surveillance.  
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